| Literature DB >> 22064272 |
Ta-Hsien Chuang1, Hsiu-Hui Chan, Tian-Shung Wu, Chien-Fu Li.
Abstract
Three new compounds: Graviquinone (1), cis-3-hydroxy-5-pentadecylcyclohexanone (2), and methyl 5-ethoxy-2-hydroxycinnamate (3), and thirty-eight known compounds were isolated and identified from the leaves of Grevillea robusta. The structures of these compounds were determined by spectroscopic and chemical transformation methods. Graviquinone (1) showed the strongest cytotoxicity against MCF-7, NCI-H460, and SF-268 cell lines. Methyl 2,5-dihydroxycinnamate (4), graviphane (13), and dehydrograviphane (14) exhibited very potent DPPH scavenging activity compared with α-tocopherol. Methyl 2,5-dihydroxycinnamate (4) and bis-norstriatol (17) demonstrated strong inhibition of L-DOPA oxidation by mushroom tyrosinase compared with kojic acid.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22064272 PMCID: PMC6264741 DOI: 10.3390/molecules16119331
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–3.
Figure 2The key HMBC (a) and NOE (b) correlations of compound 2.
Cytotoxicity of compounds 1–8, 11–18, 20, and 21 toward some cancer lines.
| Compounds | IC50 (μM) a | ||
|---|---|---|---|
| MCF-7 | NCI-H460 | SF-268 | |
|
| 15.0 ± 3.0 | 10.8 ± 2.3 | 5.9 ± 0.1 |
|
| 26.7 ± 1.9 | 42.6 ± 3.6 | 20.5 ± 0.6 |
|
| >50 | >50 | >50 |
|
| >50 | >50 | >50 |
| Actinomycin Db | 0.103 | 0.008 | 0.016 |
(a) Values were mean ± SD (n = 3–8). MCF-7 = human breast tumor cell line; NCI-H460 = human lung tumor cell line; SF-268 = human entral nervous system tumor cell line; (b) Positive control, IC50 values reported in [14].
Figure 3Structures of compounds 4, 5, 7, 8, 11–18, and 20.
DPPH inhibition activity and tyrosinase inhibition activity of compounds 1, 4, 5, 7, 8, 11–18, and 20.
| Compounds | IC50 (μM) or (Inhibition %) | |
|---|---|---|
| DPPH inhibition activity | Tyrosinase inhibition activity | |
|
| 23.01 ± 0.53 | (32.78 ± 0.54) |
|
| 0.53 ± 0.09 | 69.22 ± 1.27 |
|
| 25.68 ± 0.32 | 210.35 ± 2.13 |
|
| 28.78 ± 0.42 | (30.87 ± 0.98) |
|
| 11.78 ± 0.88 | (37.92 ± 0.67) |
|
| (28.21 ± 0.23) | 178.41 ± 2.23 |
|
| 15.67 ± 0.31 | 250.53 ± 3.26 |
|
| 3.96 ± 0.55 | (23.66 ± 0.76) |
|
| 2.05 ± 0.22 | (42.76 ± 0.53) |
|
| 36.73 ± 0.43 | 296.65 ± 3.32 |
|
| 28.93 ± 0.67 | (48.22 ± 0.43) |
|
| 31.31 ± 0.34 | 65.54 ± 0.87 |
|
| 35.22 ± 0.48 | 245.14 ± 2.21 |
|
| (21.32 ± 0.21) | 233.23 ± 1.02 |
| α-tocopherol | 3.10 ± 0.05 | - |
| Kojic acid | - | 114.54 ± 1.21 |
Percentage of inhibition (Inh %) at the 16.7 g/mL concentration; Results are presented as mean ± S.E.M (n =3). Other compounds were not tested.